RemeGen Management

Management criteria checks 2/4

RemeGen's CEO is Jianmin Fang, appointed in Oct 2008, has a tenure of 15.58 years. total yearly compensation is CN¥26.54M, comprised of 20.4% salary and 79.6% bonuses, including company stock and options. directly owns 12% of the company’s shares, worth HK$3.21B. The average tenure of the management team and the board of directors is 2.3 years and 4 years respectively.

Key information

Jianmin Fang

Chief executive officer

CN¥26.5m

Total compensation

CEO salary percentage20.4%
CEO tenure15.6yrs
CEO ownership12.0%
Management average tenure2.3yrs
Board average tenure4yrs

Recent management updates

Recent updates

RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Apr 04
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up

Is RemeGen (HKG:9995) Using Debt In A Risky Way?

Mar 24
Is RemeGen (HKG:9995) Using Debt In A Risky Way?

RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Feb 18
RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

Dec 29
Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely

RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Oct 16
RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate

Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

Aug 03
Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?

Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

Jun 22
Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?

RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

May 10
RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

Mar 09
Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?

RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

May 04
RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear

RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

Apr 08
RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially

RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

Feb 23
RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Jan 21
We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

Nov 30
Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?

We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

Oct 16
We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)

Aug 24
A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)

Here's What RemeGen Co., Ltd.'s (HKG:9995) Shareholder Ownership Structure Looks Like

Feb 09
Here's What RemeGen Co., Ltd.'s (HKG:9995) Shareholder Ownership Structure Looks Like

CEO Compensation Analysis

How has Jianmin Fang's remuneration changed compared to RemeGen's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-CN¥2b

Dec 31 2023n/an/a

-CN¥2b

Sep 30 2023n/an/a

-CN¥1b

Jun 30 2023n/an/a

-CN¥1b

Mar 31 2023n/an/a

-CN¥1b

Dec 31 2022CN¥27mCN¥5m

-CN¥999m

Sep 30 2022n/an/a

CN¥276m

Jun 30 2022n/an/a

CN¥231m

Mar 31 2022n/an/a

CN¥174m

Dec 31 2021CN¥8mCN¥4m

CN¥276m

Compensation vs Market: Jianmin's total compensation ($USD3.67M) is above average for companies of similar size in the Hong Kong market ($USD575.18K).

Compensation vs Earnings: Jianmin's compensation has increased whilst the company is unprofitable.


CEO

Jianmin Fang (61 yo)

15.6yrs

Tenure

CN¥26,544,000

Compensation

Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. She has been Director, Chief Executive Officer and served as Chief Scientific Officer of RemeGen Co. Ltd. since October 16, 2008 to 2023 and redesignated...


Leadership Team

NamePositionTenureCompensationOwnership
Jianmin Fang
Co-Founder15.6yrsCN¥26.54m12%
CN¥ 3.2b
Ruyi He
Chief Medical Officerno dataCN¥26.04m0.30%
CN¥ 79.6m
Jian Lin
Executive Directorno dataCN¥885.00kno data
Shaojing Tong
CFO & Joint Company Secretaryless than a yearno datano data
Kaisheng Huang
Chief Operating Officerno datano datano data
Marie Zhu
Chief Technical Officerno datano datano data
Zhulun Wang
Chief Scientific Officerno datano datano data
Daniel Ross
Chief Business Officerless than a yearno datano data
Xiaoming Yang
Chief Manufacturing Officerno datano datano data
Pak Yu Tam
Joint Company Secretary4yrsno datano data

2.3yrs

Average Tenure

61yo

Average Age

Experienced Management: 9995's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jianmin Fang
Co-Founder15.6yrsCN¥26.54m12%
CN¥ 3.2b
Ruyi He
Chief Medical Officer4yrsCN¥26.04m0.30%
CN¥ 79.6m
Jian Lin
Executive Director15.8yrsCN¥885.00kno data
Lorne Alan Babiuk
Member of Scientific Advisory Boardno dataCN¥125.00kno data
Gang Pei
Member of Scientific Advisory Boardno datano datano data
Weidong Wang
Co-Founder & Executive Chairman10.6yrsCN¥3.06m0.16%
CN¥ 42.3m
Liqiang Wang
Non-Executive Director4yrsno datano data
Xiaodi Su
Non-Executive Director4yrsno datano data
Xianjing Hao
Independent Non-Executive Director4yrsCN¥300.00kno data
Guangke Ren
Chairman of the Supervisory Committee4yrsno datano data
Lan Ma
Independent Non-Executive Director2.9yrsCN¥300.00kno data
Yunjin Chen
Independent Non-Executive Director2yrsCN¥200.00kno data

4.0yrs

Average Tenure

61yo

Average Age

Experienced Board: 9995's board of directors are considered experienced (4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.